FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953016584> ?p ?o ?g. }

• W2953016584 abstract "Recommendations on the optimal frequency of plasma viral load (pVL) monitoring in children living with HIV (CLWH) who are stable on combination antiretroviral therapy (cART) are inconsistent. This study aimed to determine the impact of annual versus semi-annual pVL monitoring on treatment outcomes in Asian CLWH.Data on children with perinatally acquired HIV aged <18 years on first-line, non-nucleoside reverse transcriptase inhibitor-based cART with viral suppression (two consecutive pVL <400 copies/mL over a six-month period) were included from a regional cohort study; those exposed to prior mono- or dual antiretroviral treatment were excluded. Frequency of pVL monitoring was determined at the site-level based on the median rate of pVL measurement: annual 0.75 to 1.5, and semi-annual >1.5 tests/patient/year. Treatment failure was defined as virologic failure (two consecutive pVL >1000 copies/mL), change of antiretroviral drug class, or death. Baseline was the date of the second consecutive pVL <400 copies/mL. Competing risk regression models were used to identify predictors of treatment failure.During January 2008 to March 2015, there were 1220 eligible children from 10 sites that performed at least annual pVL monitoring, 1042 (85%) and 178 (15%) were from sites performing annual (n = 6) and semi-annual pVL monitoring (n = 4) respectively. Pre-cART, 675 children (55%) had World Health Organization clinical stage 3 or 4, the median nadir CD4 percentage was 9%, and the median pVL was 5.2 log10 copies/mL. At baseline, the median age was 9.2 years, 64% were on nevirapine-based regimens, the median cART duration was 1.6 years, and the median CD4 percentage was 26%. Over the follow-up period, 258 (25%) CLWH with annual and 40 (23%) with semi-annual pVL monitoring developed treatment failure, corresponding to incidence rates of 5.4 (95% CI: 4.8 to 6.1) and 4.3 (95% CI: 3.1 to 5.8) per 100 patient-years of follow-up respectively (p = 0.27). In multivariable analyses, the frequency of pVL monitoring was not associated with treatment failure (adjusted hazard ratio: 1.12; 95% CI: 0.80 to 1.59).Annual compared to semi-annual pVL monitoring was not associated with an increased risk of treatment failure in our cohort of virally suppressed children with perinatally acquired HIV on first-line NNRTI-based cART." @default.
• W2953016584 created "2019-06-27" @default.
• W2953016584 creator A5006666582 @default.
• W2953016584 creator A5008178574 @default.
• W2953016584 creator A5009499406 @default.
• W2953016584 creator A5014680337 @default.
• W2953016584 creator A5022014506 @default.
• W2953016584 creator A5031593281 @default.
• W2953016584 creator A5038605024 @default.
• W2953016584 creator A5042491405 @default.
• W2953016584 creator A5050114438 @default.
• W2953016584 creator A5051259565 @default.
• W2953016584 creator A5056083261 @default.
• W2953016584 creator A5063430422 @default.
• W2953016584 creator A5069381510 @default.
• W2953016584 creator A5077206842 @default.
• W2953016584 creator A5080342844 @default.
• W2953016584 creator A5082475777 @default.
• W2953016584 creator A5083059000 @default.
• W2953016584 date "2019-06-01" @default.
• W2953016584 modified "2023-10-17" @default.
• W2953016584 title "Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV" @default.
• W2953016584 cites W1517608807 @default.
• W2953016584 cites W2020533061 @default.
• W2953016584 cites W2033009730 @default.
• W2953016584 cites W2102572260 @default.
• W2953016584 cites W2121743761 @default.
• W2953016584 cites W2151838240 @default.
• W2953016584 cites W2169181852 @default.
• W2953016584 cites W2560919814 @default.
• W2953016584 cites W2755255935 @default.
• W2953016584 cites W2762094441 @default.
• W2953016584 cites W2915372808 @default.
• W2953016584 cites W2953016584 @default.
• W2953016584 doi "https://doi.org/10.1002/jia2.25312" @default.
• W2953016584 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6556679" @default.
• W2953016584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31179641" @default.
• W2953016584 hasPublicationYear "2019" @default.
• W2953016584 type Work @default.
• W2953016584 sameAs 2953016584 @default.
• W2953016584 citedByCount "1" @default.
• W2953016584 crossrefType "journal-article" @default.
• W2953016584 hasAuthorship W2953016584A5006666582 @default.
• W2953016584 hasAuthorship W2953016584A5008178574 @default.
• W2953016584 hasAuthorship W2953016584A5009499406 @default.
• W2953016584 hasAuthorship W2953016584A5014680337 @default.
• W2953016584 hasAuthorship W2953016584A5022014506 @default.
• W2953016584 hasAuthorship W2953016584A5031593281 @default.
• W2953016584 hasAuthorship W2953016584A5038605024 @default.
• W2953016584 hasAuthorship W2953016584A5042491405 @default.
• W2953016584 hasAuthorship W2953016584A5050114438 @default.
• W2953016584 hasAuthorship W2953016584A5051259565 @default.
• W2953016584 hasAuthorship W2953016584A5056083261 @default.
• W2953016584 hasAuthorship W2953016584A5063430422 @default.
• W2953016584 hasAuthorship W2953016584A5069381510 @default.
• W2953016584 hasAuthorship W2953016584A5077206842 @default.
• W2953016584 hasAuthorship W2953016584A5080342844 @default.
• W2953016584 hasAuthorship W2953016584A5082475777 @default.
• W2953016584 hasAuthorship W2953016584A5083059000 @default.
• W2953016584 hasBestOaLocation W29530165841 @default.
• W2953016584 hasConcept C126322002 @default.
• W2953016584 hasConcept C127413603 @default.
• W2953016584 hasConcept C142462285 @default.
• W2953016584 hasConcept C187212893 @default.
• W2953016584 hasConcept C203014093 @default.
• W2953016584 hasConcept C2777275308 @default.
• W2953016584 hasConcept C2993143319 @default.
• W2953016584 hasConcept C3013748606 @default.
• W2953016584 hasConcept C3019165603 @default.
• W2953016584 hasConcept C71924100 @default.
• W2953016584 hasConcept C72563966 @default.
• W2953016584 hasConcept C78519656 @default.
• W2953016584 hasConceptScore W2953016584C126322002 @default.
• W2953016584 hasConceptScore W2953016584C127413603 @default.
• W2953016584 hasConceptScore W2953016584C142462285 @default.
• W2953016584 hasConceptScore W2953016584C187212893 @default.
• W2953016584 hasConceptScore W2953016584C203014093 @default.
• W2953016584 hasConceptScore W2953016584C2777275308 @default.
• W2953016584 hasConceptScore W2953016584C2993143319 @default.
• W2953016584 hasConceptScore W2953016584C3013748606 @default.
• W2953016584 hasConceptScore W2953016584C3019165603 @default.
• W2953016584 hasConceptScore W2953016584C71924100 @default.
• W2953016584 hasConceptScore W2953016584C72563966 @default.
• W2953016584 hasConceptScore W2953016584C78519656 @default.
• W2953016584 hasFunder F4320309882 @default.
• W2953016584 hasFunder F4320320439 @default.
• W2953016584 hasFunder F4320320965 @default.
• W2953016584 hasFunder F4320337346 @default.
• W2953016584 hasFunder F4320337347 @default.
• W2953016584 hasFunder F4320337351 @default.
• W2953016584 hasFunder F4320337355 @default.
• W2953016584 hasFunder F4320337611 @default.
• W2953016584 hasIssue "6" @default.
• W2953016584 hasLocation W29530165841 @default.
• W2953016584 hasLocation W29530165842 @default.
• W2953016584 hasLocation W29530165843 @default.
• W2953016584 hasLocation W29530165844 @default.
• W2953016584 hasOpenAccess W2953016584 @default.
• W2953016584 hasPrimaryLocation W29530165841 @default.
• W2953016584 hasRelatedWork W2345038251 @default.

• next